Evidence map›Paper›PMID 40405310›Full record

ArticleAlzheimer's research & therapy2025

Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer's disease.

Misato Kaishima, Junichi Ito, Kentaro Takahashi, Kenji Tai, Junro Kuromitsu, Shogyoku Bun, Daisuke Ito

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Misato KaishimaEisai-Keio Innovation Laboratory for Dementia (EKID), Deep Human Biology Learning (DHBL), Eisai Co., Ltd., Tokyo, Japan. m-kaishima@hhc.eisai.co.jp.
Junichi ItoEisai-Keio Innovation Laboratory for Dementia (EKID), Deep Human Biology Learning (DHBL), Eisai Co., Ltd., Tokyo, Japan.
Kentaro TakahashiHuman Biology Integration Foundation, DHBL, Eisai Co., Ltd., Tsukuba, Japan.
Kenji TaiEisai-Keio Innovation Laboratory for Dementia (EKID), Deep Human Biology Learning (DHBL), Eisai Co., Ltd., Tokyo, Japan.
Junro KuromitsuEisai-Keio Innovation Laboratory for Dementia (EKID), Deep Human Biology Learning (DHBL), Eisai Co., Ltd., Tokyo, Japan.
Shogyoku BunDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Daisuke ItoDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.

Funding

the Japan Agency for Medical Research and Development (AMED) JP17pc0101006
6 · The paper itself

Abstract

backgroundThe use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge this gap by developing a novel PRS model designed to predict amyloid-β (Aβ) deposition utilizing positron emission tomography (PET) imaging data from a Japanese cohort.

methodsUsing the polygenic risk score-continuous shrinkage (PRS-CS) algorithm, we calculated PRS based on significant single nucleotide polymorphisms (SNPs) associated with Alzheimer's disease (AD) in this population. We applied a PRS calculation approach informed by Japanese genome-wide association studies (GWAS) summary statistics into a Japanese dementia cohort from Keio University.

resultsOur findings revealed that a p-value threshold of pT < 0.1 optimally enhanced the predictive capability of the Japanese Aβ PET positivity risk model. Moreover, we demonstrated that distinguishing between the counts of APOE2 and APOE4 alleles in our calculations significantly elevated model performance, achieving an area under the curve (AUC) of 0.759. Remarkably, this predictive accuracy remained robust even when the pT was adjusted to be < 1.0 × 10

conclusionsThese findings highlight the potential of PRS as a noninvasive tool for early detection and risk stratification of AD, which could lead to enhanced clinical applications and interventions.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainGenetic Risk ScorePositron-Emission TomographyAgedAged, 80 and overCohort StudiesEast Asian PeopleFemaleGenome-Wide Association StudyHumansJapanMalePolymorphism, Single NucleotideAmyloid beta-PeptidesAlzheimer’s diseaseAmyloid-β depositionGenome-wide association studiesJapanese populationPolygenic risk scorePositron emission tomography

Identifiers

PMID40405310
PMCPMC12096521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.